Biosimulation Market Worth $49.2 Billion By 2030: IndustryARC

Biosimulation Market size is expected to reach $49.2 billion by 2030 after growing at a CAGR of 9.4% during the forecast period 2024-2030, according to the latest market research report published by IndustryARC. Increasing incidence of Cancer, Rising cases of the chronic diseases and the increasing investment in healthcare are set to drive the Biosimulation market, finds IndustryARC in its recent report, titled “Biosimulation Market - By Type (Software, Services), By Application ( Preclinical and Clinical Development, Drug Discovery), By End Use (Academic and Government Research Institutes, Pharmaceuticals and Biotechnological Companies, Contract Research Organizations, Regulatory Authorities) and By Geography Analysis - Global Opportunity Analysis & Industry Forecast, 2024-2030

Chronic diseases are a major public health challenge, but they are preventable. There are a number of things that individuals and governments can do to reduce the burden of chronic diseases, such as promoting healthy lifestyles, improving access to healthcare, and investing in research. As people live longer, they are more likely to develop chronic diseases. The shift from rural to urban living is associated with an increase in risk factors for chronic diseases, such as unhealthy diet, physical inactivity, and tobacco use. The spread of Western lifestyles, including high-fat, high-sugar diets and tobacco use, is contributing to the rise of chronic diseases in low- and middle-income countries. The World Health Organization (WHO) warns that NCDs, including cardiovascular diseases, cancer, diabetes, and respiratory illnesses, will account for 86% of the 90 million deaths annually by 2050. This represents a staggering 90% increase in absolute numbers since 2019.

• Software

• Services

• Preclinical and Clinical Development, Drug Discovery

• Preclinical and Clinical Development

• Drug Discovery

• Academic and Government Research Institutes

• Pharmaceuticals and Biotechnological Companies

• Contract Research Organizations

• Regulatory Authorities

• North America

• South America

• Europe

• Asia-Pacific

• Rest of the World

Geographically, North America held the largest share with 35% of the overall market in 2023, North America's dominant position in the biosimulation market is a result of a combination of factors, including a robust pharmaceutical industry, technological leadership and supportive regulatory environment. In December 2023, Pfrized completed a $43 billion acquisition of cancer and antibody-drug conjugate biologic company, Seagen. By 2030, Pfizer expects biologics such as antibody-drug conjugates (ADCs) and bispecific antibodies to contribute approximately 65% of its oncology revenues, up from 6% in 2023, a more than 10-fold increase, as per the company’s Oncology Innovation Day Presentation in February 2024. 

Drug relapse is a significant challenge in many therapeutic areas, including cancer, infectious diseases, and mental health. Biosimilars with their ability to model complex biological systems, offer a promising avenue to understand the mechanisms underlying relapse and develop strategies to prevent it. Biosimulation can be used to predict the likelihood of relapse based on patient-specific factors, such as tumor characteristics or genetic makeup. Biosimulation can contribute to the development of immune checkpoint inhibitors by modeling their impact on anti-tumor immunity and resistance mechanisms. It can help monitor minimal residual disease (MRD) and develop strategies to eradicate residual cancer cells.

Biosimulation is a powerful tool for understanding the complex dynamics of diseases. By simulating biological processes within a computational environment, researchers can gain insights into disease progression, transmission, and potential treatment strategies. Individual-based models (IBMs) focus on simulating the behavior of individual organisms, including their interactions with the environment and other individuals. These models are particularly useful for studying infectious diseases and population dynamics.  Agent-based models (ABMs) are similar to IBMs but with a greater emphasis on the interactions between agents, which can represent individuals, cells, or even molecules. ABMs are often used to model complex systems, such as tumor growth or immune response.

The intersection of AI and ML with Biosimulation is a rapidly evolving field with immense potential. By leveraging the power of these technologies, researchers and scientists are making significant strides in understanding complex biological systems, accelerating drug discovery, and improving healthcare outcomes. AI can automatically create complex biological models, optimize their parameters, and validate their accuracy. ML extracts meaningful information from biological data, integrates diverse datasets, and predicts future biological outcomes. AI identifies drug targets, screens compound, repurposes existing drugs, and improves drug behavior modeling. ML analyzes patient data to identify subgroups, optimize treatments, and deliver tailored healthcare.

According to the Environmental Working Group, by 2048 antibiotic resistance could cause more casualties than cancer. Biosimulation can play a crucial role in addressing antibiotic resistance by by modeling the evolutionary dynamics of bacteria, researchers can anticipate which antibiotics might become ineffective. Biosimulation can help in the design of novel antibiotics by simulating their interactions with bacterial targets. By modeling the pharmacokinetics and pharmacodynamics of antibiotics, researchers can determine optimal dosing and treatment durations to minimize the risk of resistance.

• Biosimulation Market size and Forecast 

• Biosimulation Market trends

• Biosimulation Market analysis by type

• CAGR of the market during the forecast period 2024-2030

• Value Chain analysis of key stake holders

• Detailed analysis of market drivers and opportunities during the forecast period

• Biosimulation Market size estimation and forecast

• Analysis and predictions on end user behavior and upcoming trends 

• Competitive landscape and Vendor market analysis including offerings, developments, and financials

• Comprehensive analysis of challenges and constraints in the Biosimulation Market

The companies profiled in the Biosimulation Market include:

• Novartis

• Pfizer 

• Catalent 

• Amgen

• Biogen

• Patheon

• Shanghai Henlius Biotech

• Vaitris

• Celltrion

• Samsung Bioepis

• ACD/Labs

• Schrödinger

• Physiomics

• LeadInvent Technologies 

• Rosa

Biomarkers Market – Biomarkers are biological molecules which act as indicator of a particular disease state or pharmacological conditions. Advancement in post genomic technologies, increasing R&D spending and dynamic applications of biomarkers in medicine will drive the future market growth.

Bioinformatics Market- Bioinformatics Market size was valued at $8.3 billion in 2020, growing at a CAGR of 12.4% during the forecast period. The recording, annotation, storage, analysis, and retrieval of nucleic acid sequence, protein sequence, and structural information are all covered by bioinformatics.

 

IndustryARC primarily focuses on Market Research and Consulting Services specific to Cutting Edge Technologies and Newer Application segments of the market. The company’s Custom Research Services are designed to provide insights into the constant flux in the global demand-supply gap of markets.  

IndustryARC’s goal is to provide the right information required by the stakeholder at the right point in time, in a format which assists an intelligent and informed decision-making process.

Mr. Venkat Reddy

IndustryARC

Email: [email protected]

Web: https://www.industryarc.com